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Introduction {#acn350844-sec-0001}
============

Mutations in the microtubule‐associated protein tau (*MAPT)* gene in chromosome 17 were described in 1998 as a cause of frontotemporal lobar degeneration (FTLD) with tau pathology.[1](#acn350844-bib-0001){ref-type="ref"}, [2](#acn350844-bib-0002){ref-type="ref"}, [3](#acn350844-bib-0003){ref-type="ref"} To date, nearly 50 pathogenic *MAPT* mutations have been reported.[4](#acn350844-bib-0004){ref-type="ref"} Clinically, FTLD related to *MAPT* mutations may affect behavior, language, memory, and executive functions. Parkinsonism has also been reported in some cases. Most *MAPT* mutations are characterized by early onset (mean 47.9 years) and a rapidly progressive clinical deterioration with a mean age at death of 58.7 years.[5](#acn350844-bib-0005){ref-type="ref"}

We describe the clinical phenotype of a novel exon 13 *MAPT* variant -- a Proline to Serine substitution at codon 397 (p.P397S) -- in eight subjects with FTLD with an autosomal dominant pattern of inheritance from five apparently nonrelated families. We hypothesize that this variant could be causative of FTLD. In addition, we compare the clinical phenotype of these cases with our series of the most frequent (p.P301L) *MAPT* mutation.[6](#acn350844-bib-0006){ref-type="ref"}

Methods {#acn350844-sec-0002}
=======

Subjects were recruited from the Genetic counseling program for familial dementias (PICOGEN program) at the Hospital Clínic de Barcelona.[7](#acn350844-bib-0007){ref-type="ref"} A detailed clinical history and neurological evaluation of all subjects were performed. We reviewed the information available from all the affected cases in the pedigrees. The diagnosis of behavioral variant frontotemporal dementia (bvFTD) was performed following the current diagnostic criteria.[8](#acn350844-bib-0008){ref-type="ref"} Cerebrospinal fluid (CSF) analysis for Alzheimer\'s disease (AD) biomarkers was measured with INNOTEST ELISAs following manufacturer\'s instructions (Fujirebio, Ghent, Belgium). Our laboratory normal reference values for amyloid beta 42 (AB42), total tau (t‐tau), and phosphorylated tau at threonine 181 (p‐tau) are \>660, \<385, and \>65 pg/mL, respectively.

Ethics {#acn350844-sec-0003}
------

This research was performed according to the guidelines of the Declaration of Helsinki. The participants provided written informed consent for genetic testing and publication of relevant findings. The study was approved by the Hospital Clínic Ethics committee.

Genetic analysis {#acn350844-sec-0004}
----------------

Genetic screening for *MAPT* (exons 1 and 9--13) and *progranulin* (*GRN*) (exons 1--13) or serum progranulin levels was performed in the eight subjects as previously described.[9](#acn350844-bib-0009){ref-type="ref"} The *MAPT* haplotype (H1/H2) was determined studying the SNP rs1800547 and *APOE* genotype with two genotyping assays (rs429358 and rs7412), using TaqMan genotyping technologies (Life Technologies, Carlsbad, CA). *C9ORF72* GGGGCC hexanucleotide repeat expansion was tested with a repeat‐primed PCR. Subject II.II.VIII was examined by exome sequencing using MedExome (Roche, Basel, Switzerland) in an Illumina NextSeq500.

We searched for functional information at ENSEMBL database (<https://www.ensembl.org>), where the variant was described as rs1295855402, and with algorithms that predict whether an amino acid substitution affects the protein function such as SIFT, Polyphen‐2, REVEL, Mutation Assessor, CADD, and MetaLR.

Statistical analysis {#acn350844-sec-0005}
--------------------

Mean age at onset, disease duration, and age at death were calculated considering together subjects with proven variant and their affected relatives. Results in p.P397S carriers were compared with our series of p.P301L using Fisher\'s exact test. Disease duration was analyzed using Kaplan--Meier estimator and compared with Log‐rank test. The analyses were performed using the SPSS Statistics Version 20.0 IBM Corp, Chicago, IL), and the level of significance was established at a *P* level of 0.05 (two‐sided).

Results {#acn350844-sec-0006}
=======

Clinical phenotype {#acn350844-sec-0007}
------------------

We include here the description of several representative cases.

### Family I {#acn350844-sec-0008}

Subject I.III.IV developed behavioral disinhibition, sweet food preference, deficits in executive tasks, and semantic language impairment at the age of 60 meeting criteria for bvFTD. MRI showed severe medial, lateral, and polar bitemporal atrophy. Currently, after 17 years of disease, she is in a stage of moderately severe dementia with severe semantic impairment scoring 5/30 at Boston Naming Test (BNT), but preserved motor functions. She had an autosomal dominant family history of dementia on her mother, aunt, grandmother, and three siblings (Fig. [1](#acn350844-fig-0001){ref-type="fig"}). All of them developed cognitive and behavioral dysfunction starting from 50 to 77 years old and showing slow disease progression. Due to this family history of dementia genetic exam was performed in subject I.III.IV and one of her brothers (subject I.III.III) revealing the presence of the p.P397S *MAPT* variant in both.

![Pedigree of the five reported families. Arrows indicate the probands described in the main text. Upper ages beneath each symbol are age at onset. Lower ages beneath each symbol are age at death.](ACN3-6-1559-g001){#acn350844-fig-0001}

### Family II {#acn350844-sec-0009}

Subject II.II.IX developed socially inappropriate behavior at the age of 64. Neuropsychological evaluation revealed short‐term memory and semantic language impairment (BNT 35/60). The MRI demonstrated moderate bitemporal atrophy (Fig. [2](#acn350844-fig-0002){ref-type="fig"}). The CSF core biomarkers analysis showed normal levels of AB42 (1308 pg/mL), but increased levels of t‐tau (414 pg/mL) and p‐tau (87 pg/mL). He had a family history of late‐onset dementia on his father, and three siblings (Fig. [1](#acn350844-fig-0001){ref-type="fig"}). The genetic study demonstrated the presence of the p.P397S variant in the *MAPT* gene. Currently, after 8 years of disease duration, he still is in a moderate stage of dementia, scoring 24 at the MMSE and 102 at the Revised Cambridge Behavioral Inventory (CBI‐R).

![MRI of subject III.II.VI showing important medial and polar bitemporal atrophy (A). Longitudinal MRI examinations of subject II.II.IX (B).](ACN3-6-1559-g002){#acn350844-fig-0002}

Subject II.II.VIII was a sibling of subject II.II.IX. He initially developed episodic and semantic memory loss and behavioral disinhibition at the age of 67. The CT scan showed bitemporal atrophy and the CSF exam presented decreased levels of AB42 (437 pg/mL) and increased t‐tau (543 pg/mL) and p‐tau (80 pg/mL), so AD diagnosis was established. During the follow‐up, the patient developed severe apathy, loss of empathy, hyperorality, and executive dysfunction, highly suggestive of bvFTD. He also presented mild rigid‐akinetic parkinsonism. Currently, after 8 years of disease progression, he scores 25 at the Mini Mental State Examination (MMSE) and he is independent for basic activities of daily living and most of the instrumental activities. The genetic test confirmed the presence of the p.P397S variant, consequently the final diagnosis of genetic bvFTD with possible concomitant AD was established.

The p.P397S *MAPT* variant was not found in subject II.II.VII, an asymptomatic 68‐year‐old sibling.

### Family III {#acn350844-sec-0010}

Subjects III.II.VI and III.II.VII were dizygotic twins. Their mother developed dementia at the age of 65. Another sibling presented clinically with behavioral impairment dysfunction strongly suggestive of bvFTD (Fig. [1](#acn350844-fig-0001){ref-type="fig"}). Subject III.II.VI presented with disinhibition, apathy, and ritualistic behaviors at the age of 63. Neuropsychological evaluation revealed impairment in memory and naming. MMSE score was 19 at the age of 69. The MRI showed severe medial bitemporal atrophy (Fig. [2](#acn350844-fig-0002){ref-type="fig"}) and the amyloid PET scan (IMM Flutemetamol‐F18) was negative. Subject III.II.VII became apathetic, exhibit diminished social interest, poor hygiene, and significantly increased smoking and alcohol intake at the age of 64. MRI demonstrated severe bitemporal atrophy. The genetic study revealed the p.P397S variant in both twins.

Summary of the clinical phenotype of p.P397S carriers {#acn350844-sec-0011}
-----------------------------------------------------

Table [1](#acn350844-tbl-0001){ref-type="table"} summarizes the demographic and clinical features of the eight subjects who are confirmed carriers of the p.P397S *MAPT* variant.

###### 

Demographic and clinical features of subjects with the p.P397S *MAPT* variant.

  Subject      Gender   Ethnicity   Age at onset (y)   Age at death (y)   Disease duration (y)   Current dementia stage   Current MMSE   Boston Naming Test   CBI‐R   Parkinsonism   Clinical Diagnosis   *MAPT* haplotype   APOE   AD biomarkers         
  ------------ -------- ----------- ------------------ ------------------ ---------------------- ------------------------ -------------- -------------------- ------- -------------- -------------------- ------------------ ------ --------------- ----- ----
  I.III.IV     Female   Caucasian   60                 Alive              16                     Moderately severe        9              5/30                 94      Yes            bvFTD                1/2                3/3    NA              NA    NA
  I.III.III    Male     Caucasian   64                 81                 17                     Dead                     --             NA                   NA      No             AD                   1/2                3/3    NA              NA    NA
  II.II.IX     Male     Caucasian   64                 Alive              8                      Moderate                 24             30/60                102     No             bvFTD                1/2                3/3    1308            414   87
  II.II.VIII   Male     Caucasian   67                 Alive              8                      Moderate                 25             35/60                NA      Yes            bvFTD                1/2                3/3    437             543   80
  III.II.VI    Female   Caucasian   63                 Alive              6                      Moderate                 19             NA                   NA      No             bvFTD                1/1                2/3    NA              NA    NA
  III.II.VII   Male     Caucasian   65                 Alive              3                      Moderate                 25             NA                   NA      No             bvFTD                NA                 NA     NA              NA    NA
  IV.II.V      Male     Caucasian   54                 Alive              18                     Severe                   0              NA                   NA      Yes            bvFTD                NA                 NA     NA              NA    NA
  V.II.III     Female   Caucasian   56                 Alive              3                      Mild                     27             31/60                22      No             bvFTD                1/2                2/3    1423            850   91

AD, Alzheimer\'s Disease; bvFTD, behavioral variant frontotemporal dementia; CBI‐R, Revised Cambridge Behavioral Inventory; NA, not available; y, years.

John Wiley & Sons, Ltd

All of them developed behavior problems and semantic language impairment. Three of them developed mild rigid‐akinetic parkinsonism. None of the subjects presented oculomotor impairment. All subjects presented bitemporal atrophy with relative frontal lobe preservation (Fig. [2](#acn350844-fig-0002){ref-type="fig"}). The frequency of these clinical symptoms does not differ from our published series of p.P301L mutation carriers.[6](#acn350844-bib-0006){ref-type="ref"}

Subjects with the p.P397S *MAPT* variant presented a significantly older age at onset than the patients with the p.P301L *MAPT* mutation (61.3 years vs. 53.5 years; *P* = 0.016). In addition, p.P397S carriers showed a significantly older age at death (76.3 years vs. 60.3 years; *P* = 0.009) and longer disease duration (14.0 years vs. 6.9 years; *P* = 0.002) (Fig. [3](#acn350844-fig-0003){ref-type="fig"}).

![Distribution of onset ages, disease durations, and ages at death associated with p.P397S and P301L *MAPT* carriers (A). Survival curves of p.P397S and P301L *MAPT* carriers (B).](ACN3-6-1559-g003){#acn350844-fig-0003}

Genetic results {#acn350844-sec-0012}
---------------

The eight patients studied carried the exon 13 *MAPT* p.P397S variant. Six of them were probands (subjects I.III.IV, II.II.IX, III.II.VI, III.II.VII, IV.II.V and V.II.III) and the other two (I.III.III and II.II.VIII) were tested after the results found in their relatives. None of them present *c9ORF72* expansion. *GRN* mutations were excluded by direct sequencing in three p.P397S carriers (subjects I.III.IV, II.II.VIII, and IV.II.V) and the rest presented normal serum progranulin levels. In addition, one subject was studied by whole‐exome sequencing (II.II.VIII) excluding any other variants in known genes involved in neurodegeneration. This novel variant was predicted as likely pathogenic according to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology guidelines and as definitively pathogenic by Guerreiro et. al. algorithm for mutation\'s pathogenicity.[10](#acn350844-bib-0010){ref-type="ref"}, [11](#acn350844-bib-0011){ref-type="ref"} In silico analysis produced different results, being predicted pathogenic by SIFT bioinformatics algorithm and probably damaging by Polyphen‐2. However, other algorithms scores prediction classified this variant as likely benign (CADD and REVEL algorithms), tolerated (MetaLR), or without a functional consequence (Mutation Assessor). This variant was not described in gnomAD database (<http://gnomad.broadinstitute.org/>) and it was present at ENSEMBL database as rs1295855402.

Discussion {#acn350844-sec-0013}
==========

In this study, we report a new *MAPT* variant (p.P397S) in eight subjects from five families suffering from FTLD with autosomal dominant pattern of inheritance. Even if the eight probands belong to five apparently nonrelated families, we could track a common geographical origin in the southeast of Spain, suggesting a possible founder effect of the p.P397S variant in this area.

We hypothesize that this new *MAPT* variant might be causative of FTLD. According to segregation analysis, their presence in eight affected bvFTD patients and their absence in one unaffected relative is predicted to be likely pathogenic in segregation analysis. In silico analysis produced discrepant results. The p.P397S variant is predicted to destroy a Proline/Serine phosphorylation site at the S396 position. Previous experimental data suggest that phosphorylation at S396 site is necessary to promote the long‐term depression at the hippocampus. In this sense, the p.P397S variant potentially will modify the physiological function of tau.[12](#acn350844-bib-0012){ref-type="ref"}, [13](#acn350844-bib-0013){ref-type="ref"}

All patients with the p.P397S variant presented clinical features consistent with the diagnosis of bvFTD. Most patients also developed semantic language impairment. Three patients developed mild rigid‐akinetic parkinsonism. These clinical features do not differ from those of patients with the p.P301L mutation. However, patients with the p.P397S *MAPT* variant showed a significantly older age at disease onset and slower disease progression compared with p.P301L mutation carriers. Neuroimaging of all patients revealed bitemporal atrophy in concordance with the typical atrophy pattern described in FTLD due to *MAPT* mutations, but with relative preservation of other areas of the brain including frontal areas.[14](#acn350844-bib-0014){ref-type="ref"}, [15](#acn350844-bib-0015){ref-type="ref"}

Mutations in the *MAPT* gene produce FTLD characterized by early onset dementia, with an age of onset between the third and fifth decade of life and 8--10 years of disease duration.[5](#acn350844-bib-0005){ref-type="ref"} However, previous studies reported that different *MAPT* mutations may show considerable phenotypic variations. This variability might be explained by the microtubule binding properties of the mutant protein.[16](#acn350844-bib-0016){ref-type="ref"} In spite of this, some mutations show an important variability in their age at onset or progression suggesting that other genetic or environmental factors can play an important role in the phenotypic expression.[17](#acn350844-bib-0017){ref-type="ref"} Only a few cases of *MAPT* mutation carriers have been reported to date presenting after the sixth decade.[18](#acn350844-bib-0018){ref-type="ref"}, [19](#acn350844-bib-0019){ref-type="ref"}, [20](#acn350844-bib-0020){ref-type="ref"} Interestingly, other mutations located at the exon 13 are also characterized by a slow rate of disease progression. The p.R406W mutation has a median age of onset of 55 (IQR 51.25--61.75) years and a median disease duration of 14 (IQR 9--26 years).[21](#acn350844-bib-0021){ref-type="ref"} As in our series, memory impairment was a marked symptom in p.R406W carriers. The p.T427M *MAPT* mutation, described only in one family, also seems to have a delayed age at onset (range 60--71 years) and death (67--79 years).[22](#acn350844-bib-0022){ref-type="ref"} However, the p.G389R mutation, also located in exon 13, has been related to an early onset presentation.[23](#acn350844-bib-0023){ref-type="ref"}

The CSF AD biomarkers were tested in three of the p.P397S carriers (subjects II.II.IX, II.II.VIII, and V.II.III). Surprisingly, levels of p‐tau ant t‐tau were increased in all three, with decreased levels of Aβ42 only in one of them. Several previous reports have described diminished CSF Aβ levels in sporadic or/and genetic FTLD.[24](#acn350844-bib-0024){ref-type="ref"}, [25](#acn350844-bib-0025){ref-type="ref"}, [26](#acn350844-bib-0026){ref-type="ref"}, [27](#acn350844-bib-0027){ref-type="ref"} It is discussed whether this finding is related to an increased deposition of Aβ spices or to a reduction of Aβ production, as it is associated with a reduction in soluble APP levels. However, in the absence of neuropathological studies in our patients, we cannot rule out the presence of concomitant AD pathology. Of note, the presence of increased p‐tau and t‐tau at CSF, in addition with the temporal lobe atrophy, some of these patients could be misdiagnosed as suffering from AD. Of course, it is not possible to discard that the presence of AD concomitant pathology was the cause of these results.

The main limitation of this study is the absence of neuropathological and direct functional data. In the absence of functional evidence, we cannot ultimately rule out the possibility that this *MAPT* variant is just a rare polymorphism. Future functional assays are needed to confirm this variant as a pathogenic mutation.

In conclusion, we report a novel *MAPT* variant, consisting in the substitution of a Proline for a Serine in the codon 397, in eight subjects from five apparently nonrelated families suffering from frontotemporal dementia with autosomal dominant pattern of inheritance. We hypothesize that this new *MAPT* variant might be causative of a less aggressive FTLD than other *MAPT* mutations. In silico analysis using several prediction software produce different results about the potential pathogenicity of this novel variant and segregation analysis predicted it to be likely pathogenic. Thus, in the absence of neuropathology or functional data, we cannot confirm this variant is definitively pathogenic. Future studies are needed in order to determine the pathogenicity of this variant.
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